Understanding the Link Between Ozempic, Wegovy, and Stomach Paralysis

Recent studies have raised concerns about the potential link between popular weight loss drugs like Ozempic and Wegovy, and severe gastrointestinal issues, including stomach paralysis, also known as gastroparesis. This article delves into the findings of these studies, providing a medical and scientific perspective on the risks associated with these medications.

What are Ozempic and Wegovy?

Ozempic and Wegovy, both containing the active ingredient semaglutide, belong to a class of drugs known as GLP-1 agonists. These drugs have been primarily used to treat Type 2 diabetes by triggering insulin release and blocking sugar production in the liver. More recently, they have been approved for weight loss in individuals with obesity. Despite their effectiveness, recent studies have highlighted the potential for serious side effects, including stomach paralysis​​​​. To learn more about FDA-approved weight loss drugs, read this article.

The Link to Stomach Paralysis

A study involving 16 million people in the US, published in JAMA, found an increased risk of gastroparesis, pancreatitis, and bowel obstruction in non-diabetic patients using these drugs for weight loss. Compared to an alternative weight loss medication, bupropion-naltrexone, patients on GLP-1 agonists had a significantly higher risk of these gastrointestinal conditions​​​​.

Study Findings and Observations

The University of British Columbia study observed that individuals using semaglutide or liraglutide were more likely to develop rare but serious gastrointestinal conditions. After adjusting for variables such as age, sex, and alcohol use, the risk of stomach paralysis was found to be more than double, and the risk of pancreatitis was eight times higher compared to those using naltrexone/bupropion​​​​.

Concerns and Considerations

While these side effects are rare, the widespread use of these drugs implies that a significant number of people could potentially experience these adverse events. Healthcare providers and patients must be aware of these risks, especially given the popularity of these medications for weight loss purposes​​.

Understanding the risks associated with weight loss medications like Ozempic and Wegovy is crucial for making informed healthcare decisions. If you're considering these weight-loss medications, consult with Dr. Carmela Mancini, MD, owner and medical director of the Weight Loss Center of the North Shore. We can help you achieve your health goals safely and effectively.

References

  • New Scientist. "Wegovy and Ozempic ingredient linked to rare stomach paralysis cases." New Scientist.

  • Global News. "Ozempic linked to stomach paralysis, other gastrointestinal issues: UBC study." Global News.

Carmela Mancini